Guardant Health has achieved a historic legal victory, securing $292.5 million, including $175.5 million in punitive damages, after a U.S. District Court jury found Natera guilty of false advertising and unfair competition. The case centered on claims that Natera misled oncologists about Guardant Reveal™, Guardant’s innovative MRD test for early-stage colorectal cancer, in favor of its competing product, Signatera™. The jury unanimously sided with Guardant and rejected all counterclaims by Natera.
Author: Abhay Panchal
Dr. Aja McCutchen, a gastroenterologist with Atlanta Gastroenterology Associates in Georgia, shares her journey into private practice gastroenterology and offers advice for a successful career. She emphasizes the importance of understanding the balance between entrepreneurship and medical practice, highlighting the need for effective negotiation skills and strategic planning. Dr. McCutchen also serves as vice chair of the AGA Research Foundation.
Lowering the positivity threshold of a commercial fecal immunochemical test (FIT) can enhance its sensitivity to levels comparable to next-generation multitarget stool DNA tests (NG-MSDT) while maintaining comparable specificity. This makes FIT a cost-effective and accessible noninvasive screening option for colorectal cancer (CRC), especially for patients who cannot undergo colonoscopies or are at lower CRC risk.A study analyzing data from the BLITZ and BLUE-C cohorts found that adjusting FIT thresholds improved sensitivity for CRC detection without significantly compromising specificity, suggesting it as a viable alternative to NG-MSDT for early CRC diagnosis and improved patient outcomes.
At DDW 2024, Dr. Rajesh N. Keswani, director of endoscopy at Northwestern Memorial Hospital, addressed common misconceptions and nonadherence to surveillance colonoscopy intervals after polypectomy. Highlighting recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer, Dr. Keswani emphasized the need for high-quality colonoscopies and adherence to updated guidelines to improve patient outcomes. His seven tips mainly focus on appropriate surveillance intervals based on polyp type and size, underscoring the importance of rectifying discordance in clinical practice to enhance the effectiveness of colorectal cancer prevention.
Medtronic has received CE Mark approval for its Endoflip 300 impedance planimetry system, designed to measure pressure and dimensions in the esophagus and pylorus, aiding in the diagnosis of esophageal motility disorders. The system addresses the challenge of delayed or missed diagnoses, which occur in up to 50% of endoscopies. The device offers real-time diameter and pressure measurements via a balloon catheter, enabling more precise diagnostics during a standard endoscopy, which can be completed in approximately five minutes. The system will soon be available across Europe and is already cleared for use in the U.S.
President-elect Donald Trump has announced plans to nominate Dr. Mehmet Oz as the administrator of the Centers for Medicare & Medicaid Services (CMS), the federal agency overseeing health coverage for over 160 million Americans. Dr. Oz, a former TV host and celebrity physician, gained fame on The Oprah Winfrey Show and his own program, though he has faced criticism for promoting controversial medical treatments lacking robust scientific support. This appointment follows Trump’s nomination of Robert F. Kennedy Jr., a vaccine skeptic, as Secretary of Health and Human Services (HHS).
In 2025, healthcare will continue to evolve with advancements in AI, biotechnology, and personalized medicine driving significant changes in planning and delivery. Personalized healthcare will focus on tailoring wellness plans using AI and data, shifting from reactive to preventative care to improve outcomes and reduce costs. Innovations like brain-computer interfaces and CRISPR gene editing will revolutionize treatments for chronic and genetic conditions, though ethical and data security concerns will grow as health data volume increases.Addressing the tech skills gap will be crucial as healthcare organizations invest in training and partnerships to harness new technologies effectively.
Frazier Healthcare Partners has closed its $2.3 billion flagship fund, Frazier Healthcare Growth Buyout Fund XI (FHGB XI), reaching its hard cap in just six months due to strong investor demand. The fund will focus on acquiring controlling stakes in middle-market healthcare companies.The Seattle-based private equity firm, with over 30 years of healthcare-focused investment experience, secured commitments from a range of global investors, including sovereign wealth funds, public pension funds, and endowments. Notably, the New Mexico State Investment Council contributed $150 million, with an additional $150 million allocated for co-investments.
Gastro Health, a leading national medical group specializing in digestive and liver health, has announced the appointment of Alan Oliver as its Chief Executive Officer. Alan has been serving as Interim CEO and Chief Operating Officer since May 2024, following his initial appointment as COO in May 2022.
Lucid Diagnostics has submitted its complete clinical evidence package to Medicare’s Molecular Diagnostics Program (MolDX), seeking reconsideration of a Local Coverage Determination (LCD) to secure Medicare coverage for its EsoGuard® Esophageal DNA Test. EsoGuard is a noninvasive diagnostic tool designed to detect esophageal precancer in patients with gastroesophageal reflux disease (GERD). The submission includes six peer-reviewed studies demonstrating the test’s clinical validity, utility, and analytical accuracy.